Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Christopher Haqq sold 6,000 shares of the firm’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $14.35, for a total value of $86,100.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Christopher Haqq also recently made the following trade(s):

  • On Friday, September 15th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $15.30, for a total value of $91,800.00.
  • On Tuesday, August 15th, Christopher Haqq sold 7,604 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $14.75, for a total value of $112,159.00.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) remained flat at $14.55 on Tuesday. The company’s stock had a trading volume of 92,090 shares. The company’s 50 day moving average price is $15.62 and its 200 day moving average price is $15.37. The firm’s market cap is $444.63 million. Atara Biotherapeutics, Inc. has a 52-week low of $11.80 and a 52-week high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). On average, equities research analysts anticipate that Atara Biotherapeutics, Inc. will post ($3.91) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/17/christopher-haqq-sells-6000-shares-of-atara-biotherapeutics-inc-atra-stock.html.

Institutional investors have recently bought and sold shares of the company. Voya Investment Management LLC increased its position in shares of Atara Biotherapeutics by 16.2% during the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 1,651 shares during the period. American International Group Inc. increased its position in shares of Atara Biotherapeutics by 7.1% during the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 948 shares during the period. State of Wisconsin Investment Board purchased a new stake in shares of Atara Biotherapeutics during the second quarter worth $252,000. The Manufacturers Life Insurance Company increased its position in shares of Atara Biotherapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 1,369 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Atara Biotherapeutics by 2.9% during the second quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after acquiring an additional 610 shares during the period. 82.95% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have commented on ATRA. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 price objective on the stock in a report on Tuesday, August 22nd. ValuEngine downgraded Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. William Blair restated an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. Jefferies Group LLC restated a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a report on Thursday, June 22nd. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $20.00 price objective on shares of Atara Biotherapeutics in a report on Friday, October 6th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. Atara Biotherapeutics has an average rating of “Hold” and a consensus target price of $24.40.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.